Information between 20th February 2025 - 12th March 2025
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Division Votes |
|---|
|
26 Feb 2025 - Family Businesses - View Vote Context Peter Fortune voted Aye - in line with the party majority and against the House One of 103 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 108 Noes - 313 |
|
26 Feb 2025 - British Indian Ocean Territory - View Vote Context Peter Fortune voted Aye - in line with the party majority and against the House One of 89 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 147 Noes - 298 |
|
24 Feb 2025 - Crown Estate Bill [Lords] - View Vote Context Peter Fortune voted Aye - in line with the party majority and against the House One of 88 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 153 Noes - 316 |
|
24 Feb 2025 - Crown Estate Bill [Lords] - View Vote Context Peter Fortune voted Aye - in line with the party majority and against the House One of 88 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 100 Noes - 312 |
|
4 Mar 2025 - Data (Use and Access) Bill [ Lords ] (First sitting) - View Vote Context Peter Fortune voted No - in line with the party majority and against the House One of 4 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 12 Noes - 4 |
|
4 Mar 2025 - Data (Use and Access) Bill [ Lords ] (First sitting) - View Vote Context Peter Fortune voted No - in line with the party majority and against the House One of 4 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 13 Noes - 4 |
|
3 Mar 2025 - Finance Bill - View Vote Context Peter Fortune voted No - in line with the party majority and against the House One of 92 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 339 Noes - 172 |
|
3 Mar 2025 - Finance Bill - View Vote Context Peter Fortune voted Aye - in line with the party majority and against the House One of 95 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 167 Noes - 347 |
|
3 Mar 2025 - Finance Bill - View Vote Context Peter Fortune voted Aye - in line with the party majority and against the House One of 96 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 176 Noes - 332 |
|
3 Mar 2025 - Finance Bill - View Vote Context Peter Fortune voted Aye - in line with the party majority and against the House One of 95 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 113 Noes - 331 |
|
4 Mar 2025 - Data (Use and Access) Bill [ Lords ] (Second sitting) - View Vote Context Peter Fortune voted No - in line with the party majority and against the House One of 4 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 10 Noes - 4 |
| Speeches |
|---|
|
Peter Fortune speeches from: Courts and Tribunals: Sitting Days
Peter Fortune contributed 1 speech (62 words) Wednesday 5th March 2025 - Commons Chamber Ministry of Justice |
|
Peter Fortune speeches from: Department for Business and Trade
Peter Fortune contributed 1 speech (339 words) Wednesday 5th March 2025 - Commons Chamber Department for Business and Trade |
|
Peter Fortune speeches from: Family Businesses
Peter Fortune contributed 1 speech (521 words) Wednesday 26th February 2025 - Commons Chamber HM Treasury |
| Written Answers | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Public Transport: Disability
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Thursday 27th February 2025 Question to the Department for Transport: To ask the Secretary of State for Transport, what steps she has taken to encourage bus and train operators to reduce levels of disability hate crime on their services. Answered by Simon Lightwood - Parliamentary Under-Secretary (Department for Transport) The government believes that everyone should be able to make journeys on public transport services without fearing that they will become a victim of crime. It is especially concerning that people should experience disability hate crime whilst using buses and trains, and operators must do all they can to challenge such unacceptable behaviour in partnership with relevant authorities.
We introduced the Bus Services (No.2) Bill which focuses on delivering safe, more reliable bus networks. The Bill sets requirements for mandatory training on how to recognise and respond appropriately to incidents of criminal and anti-social behaviour, on buses for staff, including drivers and those who deal directly with the travelling public or with issues related to the travelling public. This Bill will also extend requirements for relevant bus staff to undertake training relating to disabled passengers. Provisions in the Bus Services (No 2) Bill would also give all local transport authorities the power to make bus byelaws, which can be enforced by local authority officers on vehicles and at bus stations and stops. This, combined with targeted enforcement, should lead to safer networks. Transport Safety Officers or Transport Safety and Enforcement Officers are also already operating in some areas, including those participating in the Department’s Tackling Anti-Social Behaviour on Transport pilots.
The British Transport Police (BTP) are responsible for policing the rail network in England, Scotland and Wales. They take any reports of crime seriously, including disability hate crimes. The BTP works closely with the rail industry, including train operators, to target offenders across the network and ensure it remains a safe environment for passengers and rail staff. The BTP encourage crime to be reported via it is 61016 text number or in an emergency to call 999.
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Hidradenitis Suppurativa: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into hidradenitis suppurativa in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Epidermolysis Bullosa: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into epidermolysis bullosa in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Rosacea: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into rosacea in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Scleroderma: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into scleroderma in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Dermatitis: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into atopic dermatitis in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Alopecia: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into alopecia in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Pemphigus: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into pemphigus in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Acne: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into acne in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Psoriasis: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into psoriasis in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Skin Cancer: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into basal cell carcinoma in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Skin Cancer: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into squamous cell carcinoma in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Vitiligo: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into vitiligo in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Skin Cancer: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into melanoma in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Actinic Keratoses: Research
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill) Friday 28th February 2025 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into actinic keratosis in the 2023-24 financial year; and which public bodies provided that funding. Answered by Feryal Clark - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units. - The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis. - The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
|
| Live Transcript |
|---|
|
Note: Cited speaker in live transcript data may not always be accurate. Check video link to confirm. |
|
26 Feb 2025, 4:55 p.m. - House of Commons ">> I call Peter Fortune. >> Like many on this side of the " Llinos Medi MP (Ynys Môn, Plaid Cymru) - View Video - View Transcript |
|
26 Feb 2025, 4:55 p.m. - House of Commons ">> I call Peter Fortune. " Llinos Medi MP (Ynys Môn, Plaid Cymru) - View Video - View Transcript |
| Parliamentary Debates |
|---|
|
Department for Business and Trade
61 speeches (11,337 words) Wednesday 5th March 2025 - Commons Chamber Department for Business and Trade Mentions: 1: Harriett Baldwin (Con - West Worcestershire) the Members for Bognor Regis and Littlehampton (Alison Griffiths), for Bromley and Biggin Hill (Peter Fortune - Link to Speech |
|
Family Businesses
215 speeches (31,779 words) Wednesday 26th February 2025 - Commons Chamber HM Treasury Mentions: 1: Andrew Griffith (Con - Arundel and South Downs) Friend the Member for Bromley and Biggin Hill (Peter Fortune) reminded us that, just seven short months - Link to Speech 2: Gareth Thomas (LAB - Harrow West) Keighley and Ilkley (Robbie Moore), for West Suffolk (Nick Timothy), for Bromley and Biggin Hill (Peter Fortune - Link to Speech |
| Select Committee Documents |
|---|
|
Friday 7th March 2025
Report - 13th Report - Improving educational outcomes for disadvantaged children Public Accounts Committee Found: Caliskan (Labour; Barking) Mr Luke Charters (Labour; York Outer) Anna Dixon (Labour; Shipley) Peter Fortune |
|
Wednesday 5th March 2025
Report - 12th Report - Crown Court backlogs Public Accounts Committee Found: Caliskan (Labour; Barking) Mr Luke Charters (Labour; York Outer) Anna Dixon (Labour; Shipley) Peter Fortune |
|
Monday 3rd March 2025
Oral Evidence - Department for Energy Security and Net Zero, Ofgem, Department for Energy Security and Net Zero, Department for Energy Security and Net Zero, and Ofgem Public Accounts Committee Found: Watch the meeting Members present: Sir Geoffrey Clifton-Brown (Chair); Mr Clive Betts; Peter Fortune |
|
Friday 28th February 2025
Report - 10th Report - HS2: Update following the Northern leg cancellation Public Accounts Committee Found: Caliskan (Labour; Barking) Mr Luke Charters (Labour; York Outer) Anna Dixon (Labour; Shipley) Peter Fortune |
|
Wednesday 26th February 2025
Report - 11th Report - Excess votes 2023-24 Public Accounts Committee Found: Caliskan (Labour; Barking) Mr Luke Charters (Labour; York Outer) Anna Dixon (Labour; Shipley) Peter Fortune |
| Bill Documents |
|---|
|
Mar. 11 2025
Public Bill Committee Amendments as at 11 March 2025 Data (Use and Access) Bill [HL] 2024-26 Amendment Paper Found: _NC17 Dr Ben Spencer Alan Mak Ben Obese-Jecty Peter Fortune Joe Robertson Stuart Andrew Saqib Bhatti |
|
Mar. 10 2025
Notices of Amendments as at 10 March 2025 Data (Use and Access) Bill [HL] 2024-26 Amendment Paper Found: _NC17 Dr Ben Spencer Alan Mak Ben Obese-Jecty Peter Fortune Joe Robertson Stuart Andrew Saqib Bhatti |
|
Mar. 07 2025
Notices of Amendments as at 7 March 2025 Data (Use and Access) Bill [HL] 2024-26 Amendment Paper Found: _NC17 Dr Ben Spencer Alan Mak Ben Obese-Jecty Peter Fortune Joe Robertson Stuart Andrew Saqib Bhatti |
|
Mar. 06 2025
Notices of Amendments as at 6 March 2025 Data (Use and Access) Bill [HL] 2024-26 Amendment Paper Found: _NC17 Dr Ben Spencer Alan Mak Ben Obese-Jecty Peter Fortune Joe Robertson COMMITTEE STAGE Thursday |
|
Mar. 05 2025
Notices of Amendments as at 5 March 2025 Data (Use and Access) Bill [HL] 2024-26 Amendment Paper Found: _NC17 Dr Ben Spencer Alan Mak Ben Obese-Jecty Peter Fortune Joe Robertson ★. |
| Calendar |
|---|
|
Monday 3rd March 2025 3 p.m. Public Accounts Committee - Oral evidence Subject: The Government’s Support for Biomass View calendar - Add to calendar |
|
Thursday 3rd April 2025 9:30 a.m. Public Accounts Committee - Oral evidence Subject: Local Government Financial Sustainability View calendar - Add to calendar |